Clinical Trial Update: Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating HYQVIA in pediatric primary immunodeficiency diseases assessing efficacy, safety, tolerability, immunogenicity, and pharmacokinetics wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases

Drugs mentioned

• HYQVIA (immunoglobulin G (IgG) with recombinant human hyaluronidase)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Primary Immunodeficiency Diseases (PID) | Phase 3 | Status: COMPLETED | Results posted: 2023-10-23